Inozyme

Search

Scientific Focus
Patients and Families
Healthcare Professionals
About
Life at Inozyme
- One Energized Team
- Opportunities
Investors

Search for:

English
- 日本語 (Japanese)

Opinion: Congress Must Reauthorize FDA Program for Pediatric Rare Diseases

Contact Us
Terms of Use
Privacy Policy
Cookie Policy
Accessibility Policy

321 Summer Street, Suite 400
Boston, MA 02210

INFO@INOZYME.COM
+1 (857) 330-4340

©2025 Inozyme Pharma. All Rights Reserved.

MENU

Scientific Focus
Patients and Families
Healthcare Professionals
About
Life at Inozyme
- One Energized Team
- Opportunities
Investors

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

English
日本語 (Japanese)

Powered by GDPR Cookie Compliance

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Enable or Disable Cookies

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.